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Abstract
Background: As part of an assessment of quality of life in lung cancer patients an investigation was
carried out to examine whether the knowledge of their diagnosis affected their quality of life.
Methods: Every patient in a defined geographical area with a potential diagnosis of lung cancer was
interviewed at first consultation and after a definitive treatment has been given. Quality of life was
assessed using three standard measures: the Nottingham Health Profile (NHP), the EORTC quality
of life questionnaire (QLQ-C30) and its lung cancer supplementary questionnaire (QLQ-LC13).
Comparison was made in quality of life scores between patients who knew their cancer diagnosis
and those who did not.
Results: In all, 129 lung cancer patients were interviewed. Of these, 30 patients (23%) knew and
99 (78%) did not know their cancer diagnosis at the time of baseline assessment. The patient groups
were similar in their characteristics except for age (P = 0.04) and cell type (P < 0.0001). Overall,
there were no significant differences between these two groups with regard to their scores on the
three instruments used. A major finding was that both group scored almost the same on emotional
reactions (P = 0.8) and social isolation (P = 1.0) as measured by the NHP, and emotional (P = 0.7)
and social functioning (P = 1.0) as measured by the EORTC QLQ-C30. In addition there were no
significant differences in patients' symptom scores between those who knew their diagnosis and
those who did not, nor did any consistent pattern emerge. The only significant difference was for
sleep difficulties (P = 0.02).
Conclusion: The findings suggest that the knowledge of cancer diagnosis does not affect the way
in which patients respond to quality of life questionnaires.
Background
There is no doubt that the diagnosis of a life threatening
disease such as cancer is devastating and has an enormous
effect on one's quality of life. It is argued that cancer is not
just a single event with a certain end but a permanent con-
dition characterized by ongoing ambiguity, potentially
delayed or late effects of the disease or treatment, and con-
current psychological issues [1]. For example, studies have
shown that severe depressive illness is significantly associ-
ated with lung cancer diagnosis [2]. Thus historically there
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was a belief that a patient should not be told about his or
her cancer diagnosis. However, at present this has
changed and physicians are taught how to break 'bad
news' to patients and their family [3]. In recent years there
has been considerable attention on how to break 'bad
news' from a patient's perspective [4,5].
As far as studies of quality of life in cancer patients are
concerned, the issue of 'truth-telling' can be viewed from
a different perspective. In almost all studies, patients'
quality of life was first assessed after the diagnosis and
after or during each course of treatment. Therefore, the
question remains as to what extent does the knowledge of
diagnosis affect the results. If a patient has recently
received 'bad news' indicating that he or she has devel-
oped cancer, any assessment especially on psychological
aspects such as emotional functioning may be biased.
Those who are skeptical in assessing quality of life in can-
cer patients usually raise questions about the validity of
information collected. There appears to be no previous
research on this challenging methodological issue in the
English language literature. The only study that addressed
the topic dealt with the relationship between 'truth-tell-
ing' and quality of life. It concluded that honest disclosure
of the truth does not worsen any dimension of quality of
life in general or emotional functioning in particular [6].
This paper investigates whether the knowledge of cancer
diagnosis affects quality of life. It also investigates con-
cerns about whether systematic biases associated with
quality of life measures exist in cancer patients who knew
their diagnosis.
Methods
Study design
This was a prospective population based study of quality
of life in lung cancer patients carried out in Glasgow, Scot-
land. The study design and method of data collection are
explained in detail elsewhere [7,8]. In summary the
design of the study allowed every patient in a defined geo-
graphical area with a potential diagnosis of lung cancer
attending a large general and teaching hospital to be inter-
viewed from first outpatient consultation until after a
definitive treatment has been given. Thus, both patients
and the interviewer were blind to the final diagnosis at the
time of the pre-diagnosis interview. However, in some
instances because of quick referrals and logistic problems
the assessments were made after the diagnosis and before
the start of the treatment. Therefore, these patients were
interviewed while they knew their diagnosis. In other
words at baseline assessment there were two groups of
lung cancer patients: those who were interviewed before
diagnosis (not knowing group) and those who were inter-
viewed after formal disease disclosure by the chest clinic
team or their general practitioners (knowing group). Fol-
low-up assessments within three months of diagnosis
were carried out for those with a confirmed diagnosis of
lung cancer, but for the purpose of this study analysis was
restricted to the baseline (pre-diagnosis) assessments.
Instruments
Quality of life was assessed using three standard meas-
ures: (i) the Nottingham Health Profile (NHP), a general
health measure including profiles on energy, pain, emo-
tional reactions, social isolation, sleep, and physical
mobility [9], (ii) the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30), a core cancer-specific questionnaire
containing 30 items on patients' functioning, global qual-
ity of life, disease- and treatment related symptoms [10],
and (iii) the EORTC Lung Cancer Questionnaire (EORTC
QLQ-LC13), a site-specific questionnaire consisting of 13
items on lung cancer symptoms and its treatment related
side-effects [11].
Data on the social and demographic characteristics of the
patients and clinical information including performance
status, weight loss, histology, extent of disease, and treat-
ment were extracted from case records.
Analysis
Since most measures were not normally distributed, the
Mann-Whitney U-test was performed to compare quality
of life scores between the two patient groups at baseline
(those who knew their cancer diagnosis versus those who
did not). For categorical data comparison was made using
the chi-square test.
Results
Patients' characteristics
In all, 238 patients were interviewed. Of these, 129
patients had a confirmed diagnosis of lung cancer and 109
were patients with chronic respiratory disease. There were
no significant differences between lung cancer patients
and patients with respiratory disease except for age
(patients with respiratory disease were younger). In addi-
tion with regards to quality of life scores at baseline there
were no significant differences between lung cancer
patients and patients with respiratory disease except for
pain and appetite loss (lung cancer patients had a greater
degree of symptoms. Data are not shown but is available
form the corresponding author). However, among lung
cancer patients, 30 patients (23%) were interviewed while
they knew their cancer diagnosis and 99 patients (77%)
were interviewed while they did not their cancer diagno-
sis. In general there were no significant differences
between the characteristics of patient groups except for
age and cell type; patients who knew their diagnosis were
younger (P = 0.04) and were more likely to have small cellBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/21
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lung cancer (P < 0.0001). The characteristics of the
patients are shown in Table 1.
General health and functioning
Patient' general health as measured by the NHP and func-
tioning and global quality of life scores as measured by
the EORC QLQ-C30 are presented in Tables 2 and 3
respectively. There were no significant differences
between the two groups' scores. Even patients' scores on
emotional reactions and social isolation or emotional and
social functioning were almost the same. However,
patients who knew their diagnosis had more perceived
health problems in terms of physical mobility, energy and
a poor level of functioning in terms of physical and role
functioning.
Symptoms
Patients' main symptom scores as measured by the
EORTC QLQ-C30 and QLQ-LC13 are listed in Table 4.
Again there were no significant differences between the
two groups indicating that those who knew their diagno-
sis and those who did not perceived their symptoms in a
similar way. However those who did not know their can-
cer diagnosis reported significant sleep difficulties com-
pared to those patients who knew their diagnosis (P =
0.02).
Discussion
This study provides evidence to suggest that the knowl-
edge of cancer diagnosis does not affect the way in which
patients respond to a quality of life questionnaire. How-
ever, this does not mean that cancer diagnosis does not
affect people's life. Looking at the scores for the two
groups clearly indicate that these patients even at the pre-
diagnosis stage had several health problems as well as
symptoms related to lung cancer.
The intention here is to show that knowing or not know-
ing one's cancer diagnosis does not make any significant
difference to the patients' responses to a quality of life
questionnaire; either a general health questionnaire (the
NHP), one that is cancer-specific (the EORTC QLQ-C30)
or one that is site-specific (the EORTC QLQ-LC13). It is
important to realize that the NHP and the EORTC quality
of life questionnaires are very well developed instruments
in nature [12,13] and provided a valid means for examin-
Table 1: Lung cancer patients' characteristics
Study sample (n = 129) 
No. (%)
Did not know (n = 99) 
No. (%)
Knew (n = 30) No. (%) P*
Gender
Male 77 (60) 58 (59) 19 (63)
Female 52 (40) 41 (41) 11 (37) 0.64
Age (year)
Mean (SD) 67.5 (9.1) 68.4 (9.0) 64.5 (8.7) 0.04
Marital status
Married 77 (60) 55 (56) 22 (73)
Widowed/single 52 (40) 44 (44) 8 (27) 0.08
Extent of disease
Limited 101 (78) 80 (80) 21 (70)
Extensive 28 (22) 19 (20) 9 (30)) 0.21
Cell type
Non-small cell 67 (52) 57 (58) 10 (33)
Small cell 27 (21) 12 (12) 15 (50)
Unspecified 35 (27) 30 (30) 5 (17) < 0.0001
Performance status (score)
Normal activity (0) 29 (23) 23 (23) 6 (20)
Symptoms (1) 60 (47) 47 (48) 13 (43)
Sometimes in bed (2) 25 (19) 20 (20) 5 (17)
Need to be in bed (3) 15 (11) 9 (9) 6 (20)
Confined to bed (4) 0 (00) 0 (00) 0 (00) 0.44
Weight loss
Significant weight loss 51 (40) 39 (39) 12 (40)
Weight steady 40 (31) 30 (31) 10 (36)
Possible weight loss/no comment on 
case records
38 (29) 30 (31) 8 (30) 0.53
* χ2 test for categorical data and Mann-Whitney U-test for continuous variables.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/21
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ing the study question. None of these instrument contain
the word 'cancer' or other related terminology that would
alert patients.
The striking findings in this study were that patients'
scores on emotional reactions and social isolation (on the
NHP) or emotional and social functioning (on the
EORTC QLQ-C30) were very similar in the two groups. If
Table 2: Patients' scores on the NHP (the higher values indicate more perceived health problems, min.: 0, max.: 100)
Did not know (n = 99) Knew (n = 30) P*
Mean (SD) Mean (SD)
Physical mobility 27.7 (27.2) 38.5 (29.5) 0.07
Energy 40.8 (42.0) 49.1 (40.3) 0.3
Emotional reactions 25.6 (24.6) 26.2 (23.0) 0.8
Social isolation 12.9 (22.8) 11.9 (19.5) 1.0
Pain 26.3 (30.2) 18.6 (25.4) 0.2
Sleep 39.7 (32.9) 33.7 931.0) 0.5
* Mann-Whitney U-test.
Table 3: Patients' functioning and global quality of life scores as measured by the EORTC QLQ-C30 (the higher values indicate a higher 
level of functioning and quality of life, min.: 0, max.: 100)
Did not know (n = 99) Knew (n = 30) P*
Mean (SD) Mean (SD)
Physical functioning 64.2 (26.8) 54.0 (28.8) 0.1
Role functioning 62.1 (36.5) 48.3 (38.2) 0.08
Emotional functioning 78.1 (21.8) 79.4 (21.0) 0.7
Social Functioning 87.5 (22.0) 85.0 (27.5) 1.0
Cognitive functioning 85.0 (21.0) 87.2 (20.8) 0.4
Global quality of life 49.2 (22.5) 51.7 (25.2) 0.9
* Mann-Whitney U-test.
Table 4: Patients' symptom scores on the EORTC QLQ-C30 and QLQ-LC13 (the higher values indicate a greater degree of symptoms, 
min.: 0, Max.: 100)
Did not know (n = 99) Knew (n = 30) P*
Mean (SD) Mean (SD)
Cough 46.8 (33.0) 46.7 (32.3) 1.0
Haemoptysis 10.1 (23.5) 10.0 (23.4) 1.0
Dyspnoae 37.0 (27.1) 39.7 (28.8) 0.7
Pain (overall) 29.1 (29.2) 20.6 (26.5) 0.2
Pain in chest 22.2 (29.4) 20.0 (27.1) 0.8
Pain in arm and shoulder 30.0 (35.2) 18.9 (32.4) 0.1
Pain elsewhere 22.9 (32.2) 31.1 (37.1) 0.2
Sleep difficulties 34.7 (37.8) 17.8 (32.4) 0.02
Fatigue 37.4 (30.5) 37.0 (25.2) 0.8
Appetite loss 32.3 (34.8) 41.1 (32.4) 0.1
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diagnosis had any effect on patients' responses then one
might expect to see, if not significant, at least much higher
differences between these two groups' scores on such
measures. Yet, patients who knew their cancer diagnosis
showed a slightly better global quality of life score (Table
3).
The findings indicated that there were slight differences
between patient's scores for some measures. For example,
patients who knew their diagnosis reported more prob-
lems with physical mobility, and energy, and had lower
physical and role functioning. Certainly this was not due
to their age differences since those who knew their cancer
diagnosis were significantly younger than the other group.
With regards to patients' symptom scores, again there
were no significant differences between the two groups,
indicating that the knowledge of their cancer diagnosis
did not lead to an overestimation of symptoms by
patients who knew they had developed lung cancer. The
only significant difference observed was for sleep difficul-
ties showing that those who did not know their diagnosis
had more problems. However it not clear why such a dif-
ference emerged but one explanation is that this group of
patients was older than the other group and this may have
contributed to the problem.
In summary, the findings from the present study indicate
that knowledge of a diagnosis of cancer does not affect the
way in which patients respond to a quality of life ques-
tionnaire. This was based on the fact that patients who
knew their cancer diagnosis and those who did not,
responded similarly to most measures studied especially
the psychosocial ones. The findings confirm that baseline
assessment of quality of life in a cancer patient with
knowledge of their diagnosis can be considered valid pro-
viding that other methodological prerequisites are appro-
priately dealt with.
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